GlassScriptPhysician profile
Thomas C Bartzokis
NPI 1053355560
$11,346.97
in general payments reported to CMS, 2019-2025
45 companies · $1,326 in 2025
The $1,326 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,017 · 2020: $1,256 · 2021: $1,603 · 2022: $1,989 · 2023: $1,525 · 2024: $1,631 · 2025: $1,326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,482.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,676.69 | 2019-2025 | |
| Amgen INC. | $1,241.06 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $1,199.61 | 2019-2025 | |
| Abbott Laboratories | $1,163.46 | 2019-2025 | Aveir, Jot Dx, Confirm Rx |
| Janssen Pharmaceuticals, INC | $1,009.15 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $612.67 | 2019-2025 | Camzyos, Eliquis |
| Amarin Pharma, INC. | $422.48 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $384.72 | 2021-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $336.67 | 2019-2025 | Jardiance |
| Philips North America LLC | $298.07 | 2022-2025 | Ambulatory Monitoring & Diagnostics Undivided, (5091) Amb Mon & Diag Und |
| Astrazeneca Pharmaceuticals LP | $261.76 | 2019-2025 | Farxiga |
| Sanofi-Aventis U.S. LLC | $248.48 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $237.52 | 2020-2023 | Lifevest |
| Kestra Medical Technology Services, INC. | $237.14 | 2024-2025 | Assure Wcd |
| Kowa Pharmaceuticals America, INC. | $229.25 | 2019-2024 | Livalo |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $192.96 | 2019-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Heartflow, INC. | $182.10 | 2022-2024 | Ffrct |
| Bayer Healthcare Pharmaceuticals INC. | $121.32 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $117.79 | 2019-2025 | Evkeeza, Praluent |
| Medtronic, INC. | $117.05 | 2021-2025 | Aurora Ev-Icd Mri Surescan |
| Chiesi USA, INC. | $84.55 | 2019-2024 | Kengreal |
| Kiniksa Pharmaceuticals, LTD. | $80.80 | 2022-2023 | Arcalyst |
| Cleerly, INC. | $78.65 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Lexicon Pharmaceuticals, INC. | $75.40 | 2023 | Inpefa |
| Cvrx, INC. | $73.61 | 2023-2025 | Barostim Neo System |
| Novo Nordisk INC | $70.38 | 2021-2024 | Wegovy |
| Medtronic Vascular, INC. | $62.27 | 2019 | |
| Bridgebio Pharma, INC. | $59.38 | 2025 | Attruby |
| Kiniksa Pharmaceuticals International, Plc | $54.37 | 2024 | Arcalyst |
| Irhythm Technologies, INC. | $49.21 | 2023 | Zio Xt Patch |
| Agepha Pharma Fz LLC | $44.20 | 2024-2025 | Lodoco |
| Alnylam Pharmaceuticals INC. | $38.75 | 2022-2023 | Onpattro |
| Siemens Medical Solutions USA, INC. | $37.12 | 2020 | |
| Esperion Therapeutics, INC. | $35.67 | 2025 | Nexletol |
| Zoll Circulation INC | $32.00 | 2021 | |
| Lundbeck LLC | $22.48 | 2020 | |
| Atricure, INC. | $21.84 | 2021 | |
| Amryt Pharma Holdings LTD | $21.02 | 2021 | |
| Akcea Therapeutics, INC. | $20.86 | 2020 | |
| Arbor Pharmaceuticals, INC. | $17.96 | 2019 | |
| Vital Connect, INC | $17.62 | 2025 | Vitalpatch Rtm |
| Astellas Pharma US INC | $16.37 | 2019 | |
| Bardy Diagnostics, INC. | $15.00 | 2022 | |
| Genzyme Corporation | $13.91 | 2023 | |
| Cardiva Medical, INC. | $13.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Bartzokis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.